The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Is there a role for PDE5 inhibitors in the management of male infertility due to defects in testicular or epididymal function?

TitleIs there a role for PDE5 inhibitors in the management of male infertility due to defects in testicular or epididymal function?
Publication TypeJournal Article
Year of Publication2009
AuthorsDimitriadis, F., Tsounapi P., Saito M., Watanabe T., Sylakos A., Tsabalas S., Miyagawa I., & Sofikitis N.
JournalCurr Pharm Des
Volume15
Issue30
Pagination3506-20
Date Published2009
ISSN1873-4286
KeywordsAcrosome Reaction, Cyclic GMP, Cyclic Nucleotide Phosphodiesterases, Type 5, Epididymis, Genital Diseases, Male, Genitalia, Male, Humans, Infertility, Male, Leydig Cells, Male, Phosphodiesterase 5 Inhibitors, Phosphodiesterase Inhibitors, Semen, Seminiferous Tubules, Sertoli Cells, Sperm Capacitation, Spermatozoa, Testicular Diseases
Abstract

This review study refers to the possibility to employ PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest that PDE5 inhibitors enhance the Leydig cell secretory function and play a role in the regulation of the contractility of the tunica albuginea and the epididymis. In addition, the literature suggests that PDE5 inhibitors increase the prostatic secretory function that results in an improvement in sperm motility in several cases. Some studies additionally demonstrate a role of PDE5 inhibitors in the regulation of sperm capacitation process. Additional placebo-controlled, randomized, blind studies are necessary to unequivocally suggest a therapeutic role of PDE5 inhibitors in the alleviation of semen disorders and male infertility.

DOI10.2174/138161209789207015
Alternate JournalCurr Pharm Des
PubMed ID19860697

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.